JP2026004299A5 - - Google Patents

Info

Publication number
JP2026004299A5
JP2026004299A5 JP2025145375A JP2025145375A JP2026004299A5 JP 2026004299 A5 JP2026004299 A5 JP 2026004299A5 JP 2025145375 A JP2025145375 A JP 2025145375A JP 2025145375 A JP2025145375 A JP 2025145375A JP 2026004299 A5 JP2026004299 A5 JP 2026004299A5
Authority
JP
Japan
Prior art keywords
polypeptide
cdr
amino acid
extended recombinant
recombinant polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025145375A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026004299A (ja
Filing date
Publication date
Priority claimed from JP2022578997A external-priority patent/JP2023531494A/ja
Application filed filed Critical
Publication of JP2026004299A publication Critical patent/JP2026004299A/ja
Publication of JP2026004299A5 publication Critical patent/JP2026004299A5/ja
Pending legal-status Critical Current

Links

JP2025145375A 2020-06-25 2025-09-02 Her-2標的化二重特異性組成物ならびにその作製および使用のための方法 Pending JP2026004299A (ja)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US202063044301P 2020-06-25 2020-06-25
US63/044,301 2020-06-25
US202063077503P 2020-09-11 2020-09-11
US63/077,503 2020-09-11
US202063108783P 2020-11-02 2020-11-02
US63/108,783 2020-11-02
US202163166857P 2021-03-26 2021-03-26
US63/166,857 2021-03-26
US202163196408P 2021-06-03 2021-06-03
US63/196,408 2021-06-03
JP2022578997A JP2023531494A (ja) 2020-06-25 2021-06-24 Her-2標的化二重特異性組成物ならびにその作製および使用のための方法
PCT/US2021/039006 WO2021263058A1 (en) 2020-06-25 2021-06-24 Her-2 targeted bispecific compositions and methods for making and using the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022578997A Division JP2023531494A (ja) 2020-06-25 2021-06-24 Her-2標的化二重特異性組成物ならびにその作製および使用のための方法

Publications (2)

Publication Number Publication Date
JP2026004299A JP2026004299A (ja) 2026-01-14
JP2026004299A5 true JP2026004299A5 (https=) 2026-03-09

Family

ID=79281898

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022578997A Pending JP2023531494A (ja) 2020-06-25 2021-06-24 Her-2標的化二重特異性組成物ならびにその作製および使用のための方法
JP2025145375A Pending JP2026004299A (ja) 2020-06-25 2025-09-02 Her-2標的化二重特異性組成物ならびにその作製および使用のための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022578997A Pending JP2023531494A (ja) 2020-06-25 2021-06-24 Her-2標的化二重特異性組成物ならびにその作製および使用のための方法

Country Status (12)

Country Link
US (2) US20230322922A1 (https=)
EP (1) EP4172179A4 (https=)
JP (2) JP2023531494A (https=)
KR (1) KR20230041711A (https=)
AU (2) AU2021297984C1 (https=)
BR (1) BR112022026420A2 (https=)
CA (1) CA3182372A1 (https=)
CO (1) CO2023000247A2 (https=)
IL (1) IL298815A (https=)
MX (1) MX2022016387A (https=)
PH (1) PH12022553407A1 (https=)
WO (1) WO2021263058A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023531494A (ja) 2020-06-25 2023-07-24 アムニクス ファーマシューティカルズ, インコーポレイテッド Her-2標的化二重特異性組成物ならびにその作製および使用のための方法
CN121426967A (zh) 2023-02-10 2026-01-30 阿穆尼克斯制药公司 靶向前列腺特异性膜抗原(psma)的组合物及其制备和使用方法
EP4683718A1 (en) 2023-04-17 2026-01-28 Amunix Pharmaceuticals, Inc. Compositions targeting epidermal growth factor receptor and methods for making and using the same
WO2025122957A1 (en) 2023-12-08 2025-06-12 Amunix Pharmaceuticals, Inc. Protease activatable cytokines and methods for making and using the same
GB2641580A (en) * 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins
WO2026024863A2 (en) 2024-07-24 2026-01-29 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4284444A (en) 1977-08-01 1981-08-18 Herculite Protective Fabrics Corporation Activated polymer materials and process for making same
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4200984A (en) 1979-03-12 1980-05-06 Fink Ray D Detachable tool combining bracket and method
US4398908A (en) 1980-11-28 1983-08-16 Siposs George G Insulin delivery system
US4435173A (en) 1982-03-05 1984-03-06 Delta Medical Industries Variable rate syringe pump for insulin delivery
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5231112A (en) 1984-04-12 1993-07-27 The Liposome Company, Inc. Compositions containing tris salt of cholesterol hemisuccinate and antifungal
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
JPS61502760A (ja) 1984-07-24 1986-11-27 キイ・フア−マシユ−テイカルズ・インコ−ポレイテツド 粘着性経皮投与層
US4684479A (en) 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US6759057B1 (en) 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US4933185A (en) 1986-09-24 1990-06-12 Massachusetts Institute Of Technology System for controlled release of biologically active compounds
US6406713B1 (en) 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
US4976696A (en) 1987-08-10 1990-12-11 Becton, Dickinson And Company Syringe pump and the like for delivering medication
US4861800A (en) 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
AU598958B2 (en) 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
GB8807504D0 (en) 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
JP2717808B2 (ja) 1988-08-10 1998-02-25 テルモ株式会社 シリンジポンプ
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5017378A (en) 1989-05-01 1991-05-21 The University Of Virginia Alumni Patents Foundation Intraorgan injection of biologically active compounds contained in slow-release microcapsules or microspheres
US5298022A (en) 1989-05-29 1994-03-29 Amplifon Spa Wearable artificial pancreas
US5318540A (en) 1990-04-02 1994-06-07 Pharmetrix Corporation Controlled release infusion device
US5492534A (en) 1990-04-02 1996-02-20 Pharmetrix Corporation Controlled release portable pump
US5176502A (en) 1990-04-25 1993-01-05 Becton, Dickinson And Company Syringe pump and the like for delivering medication
US5215680A (en) 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5660848A (en) 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
CA2263455C (en) 1996-08-23 2002-10-29 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
SK283760B6 (sk) 1996-10-15 2004-01-08 The Liposome Company, Inc. Farmaceutický prostriedok na dopravu bioaktívnych látok
US6361796B1 (en) 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
ATE314054T1 (de) 1996-10-25 2006-01-15 Shire Lab Inc Osmotisches verabreichungssystem für lösliche dosen
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
DE69838526T2 (de) 1998-02-05 2008-07-03 Biosense Webster, Inc., Diamond Bar Gerät zum Freisetzen eines Medikaments im Herzen
US6406632B1 (en) 1998-04-03 2002-06-18 Symyx Technologies, Inc. Rapid characterization of polymers
GB9815157D0 (en) 1998-07-13 1998-09-09 Metron Designs Ltd High resolution pulse width setting from relatively low frequency clocks
US6713086B2 (en) 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
NZ514442A (en) 1999-03-03 2003-08-29 Optinose As Nasal delivery device
US6183770B1 (en) 1999-04-15 2001-02-06 Acutek International Carrier patch for the delivery of agents to the skin
US6743211B1 (en) 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6352721B1 (en) 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
US20030228309A1 (en) 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
IN190699B (https=) 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US6890918B2 (en) 2001-04-30 2005-05-10 Shire Laboratories, Inc. Pharmaceutical compositions including ACE/NEP inhibitors and bioavailability enhancers
US6838093B2 (en) 2001-06-01 2005-01-04 Shire Laboratories, Inc. System for osmotic delivery of pharmaceutically active agents
KR100407467B1 (ko) 2001-07-12 2003-11-28 최수봉 리모컨 방식의 인슐린 자동주사기
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
US7294513B2 (en) 2002-07-24 2007-11-13 Wyatt Technology Corporation Method and apparatus for characterizing solutions of small particles
JP5139800B2 (ja) 2004-06-03 2013-02-06 ノビミューン エスアー 抗cd3抗体およびその使用方法
AR057807A1 (es) 2005-09-12 2007-12-19 Novimmune Sa Formulaciones de anticuerpo anti-cd3
NZ591087A (en) 2008-10-01 2012-08-31 Micromet Ag Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
JP5839597B2 (ja) 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド グルコース調節ポリペプチド並びにその作成及び使用方法
SI2440241T1 (sl) 2009-06-08 2017-11-30 Amunix Operating Inc. Polipeptidni rastni hormoni in postopki za njihovo izdelavo in uporabo
AU2010290131C1 (en) 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
WO2011123830A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
EP2552967A4 (en) 2010-04-02 2014-10-08 Amunix Operating Inc BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
HRP20200007T1 (hr) 2012-07-11 2020-03-20 Bioverativ Therapeutics Inc. Kompleks proteina faktora viii s xten i von willebrandovim faktorom, te njegova uporaba
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
MX2017006016A (es) * 2014-11-11 2017-06-19 Amunix Operating Inc Composiciones conjugadas de xten direccionadas y metodos para producir las mismas.
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
EP3728326A4 (en) * 2017-12-21 2021-12-15 Amunix Pharmaceuticals, Inc. SEPARATING SEGMENTS AND BINDING COMPOSITIONS THEREFORE
SG11202007572VA (en) * 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
US20230121775A1 (en) * 2019-06-26 2023-04-20 Amunix Pharmaceuticals, Inc. Cd3 antigen binding fragments and compositions comprising same
CA3143522A1 (en) 2019-06-26 2020-12-30 Amunix Pharmaceuticals, Inc. Egfr antigen binding fragments and compositions comprising same
CN115175920B (zh) * 2019-11-13 2025-10-31 阿穆尼克斯制药公司 加条形码的xten多肽及其组合物以及其制备和使用方法
JP2023531494A (ja) 2020-06-25 2023-07-24 アムニクス ファーマシューティカルズ, インコーポレイテッド Her-2標的化二重特異性組成物ならびにその作製および使用のための方法

Similar Documents

Publication Publication Date Title
JP2026004299A5 (https=)
US20240124584A1 (en) Igm fc and j-chain mutations that affect igm serum half-life
JP2021159081A5 (https=)
JP2022079549A5 (https=)
TWI531377B (zh) 骨關節炎及疼痛之治療
NZ717476A (en) Anti-garp protein and uses thereof
JP2018502050A5 (https=)
AR040046A1 (es) Anticuerpo neutralizante humano anti-igfr
KR20120089659A (ko) 치료용 dll4 결합 단백질
JP2020500510A5 (https=)
JPWO2019234220A5 (https=)
JP2025032102A5 (https=)
RU2006115835A (ru) Человеческие антитела против человеческого 4-1вв (cd137)
JP2020505919A5 (https=)
JP2005528914A5 (https=)
JP2018512124A5 (https=)
JP2019504615A5 (https=)
JP2024119984A5 (https=)
JP2020522475A5 (https=)
JPWO2021116182A5 (https=)
JPWO2022224997A5 (https=)
JP2012502663A5 (https=)
JPWO2020264208A5 (https=)
JPWO2021263058A5 (https=)
JPWO2022073138A5 (https=)